Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
OMP-52M51
DRUG
2 trials
Sponsors
OncoMed Pharmaceuticals, Inc.
Conditions
Relapsed or Refractory Lymphoid Malignancies
Relapsed or Refractory Solid Tumors
Phase 1
A Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies
Completed
NCT01703572
OncoMed Pharmaceuticals, Inc.
Relapsed or Refractory Lymphoid Malignancies
Start: 2012-10-31
End: 2016-01-31
Updated: 2020-09-09
A Dose Escalation Study of OMP-52M51 in Subjects With Solid Tumors
Completed
NCT01778439
OncoMed Pharmaceuticals, Inc.
Relapsed or Refractory Solid Tumors
Start: 2013-02-28
End: 2016-07-31
Updated: 2020-08-11
Related Papers
A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors.
2018-07-01
106 citations
Safety and Preliminary Efficacy Results of a Phase I First-in-Human Study of the Novel Notch-1 Targeting Antibody Brontictuzumab (OMP-52M51) Administered Intravenously to Patients with Hematologic Malignancies
Blood
2016-12-02
37 citations
Abstract C42: Safety and preliminary efficacy results of a first-in-human phase I study of the novel cancer stem cell (CSC) targeting antibody brontictuzumab (OMP-52M51, anti-Notch1) administered intravenously to patients with certain advanced solid tumors
Molecular Cancer Therapeutics
2015-12-01
8 citations
Abstract 1549: Development and validation of a biomarker for prospective selection of Notch1 activation in patients with certain advanced solid tumors in a first-in-human phase1 study of the cancer stem cell targeting antibody OMP-52M51 (anti-Notch1)
Cancer Research
2015-08-01
1 citations